|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-8-27
|
|
pubmed:abstractText |
In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG-DOXO) was effective as second-line therapy for patients with cutaneous T-cell lymphoma (CTCL). The objective of this study was to evaluate the efficacy and toxicity of single-agent PEG-DOXO as second-line chemotherapy in patients with CTCL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
993-1001
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12942567-Adult,
pubmed-meshheading:12942567-Aged,
pubmed-meshheading:12942567-Aged, 80 and over,
pubmed-meshheading:12942567-Antineoplastic Agents,
pubmed-meshheading:12942567-Disease-Free Survival,
pubmed-meshheading:12942567-Doxorubicin,
pubmed-meshheading:12942567-Female,
pubmed-meshheading:12942567-Humans,
pubmed-meshheading:12942567-Liposomes,
pubmed-meshheading:12942567-Lymphoma, T-Cell, Cutaneous,
pubmed-meshheading:12942567-Male,
pubmed-meshheading:12942567-Middle Aged,
pubmed-meshheading:12942567-Retrospective Studies,
pubmed-meshheading:12942567-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
|
|
pubmed:affiliation |
Department of Dermatology, Hospital Dresden-Friedrichstadt, Friedrichstrasse 41, 01067 Dresden, Germany. wollina-uw@khdf.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
